Czech and Slovak Ophthalmology 51 Original article Ocular Cicatricial Pemphigoid – a Retrospective Study Szabó Eva Palos Michalis Skalická Pavlína 30 1 2016 1 4

Introduction: Ocular cicatricial pemphigoid (OCP) is rare, severe, sight threatening autoimmune disease of the conjunctiva, which affects elderly patients, more often women. Aim: To evaluate the success rate of stabilisation of ocular findings in patients with OCP. Methods: Retrospective study of patients from Centre of Conjunctival and Corneal Diseases at Department of Ophthalmology, General University Hospital and 1st Medical Faculty of Charles University in Prague in 1992-2013 was performed. Frequency of OCP clinical stages, visual acuity (VA), disease activity and ocular complications of referred patients were monitored. Moreover, type of immunosuppressive (IS) therapy, the number of relapses of the disease and progress of OCP clinical stages were evaluated. Especially, we evaluated effects and side effects of mycophenolate mofetil (MM) therapy. In addition to that, type and frequency of ocular surgery that was carried out to the patients before and after the referral were recorded. Furthermore, we evaluated percentage of patients with mucous membranous pemphigoid (MMP). Also, the positive yield of diagnostic methods was assessed. Results: The OCP was diagnosed and monitored in 51 patients (21 men and 30 women) during 21 years, the average age on the day of diagnosis was 68,4 years, the average period of observation was 57 months. 55 % of eyes were referred to our department at clinical stage 3, 27 % at stage 4. VA was maintained in 76 % of eyes, improved in 5 % of eyes and in 19 % of eyes deteriorated. Activity of OCP was detected during the first examination in 96 % of patients, the most common complications at that time was corneal ulcer or perforation. Patients were treated by immunosuppressive therapy, most often in combination: corticosteroids (47 patients), azathioprine (28 patients), cyclophosphamide (25 patients), MM (16 patients), sulphasalazine (5 patients), dapsone (5 patients). We ascertained relapses in 40 % of patients. The progression to the next stage of OCP were found in 7 eyes (6,9 %) and 95 eyes (93,1 %) remained stable. Activity of disease was well controlled in 11 patients out of 16 (69 %) by MM, IS therapy of remain 5 patients (31 %) had to be changed. Side effects of MM such as lymphopenia were present in 1 patient. Before OCP was diagnosed, patients underwent cataract surgery with the intraocular lens implantation, cryoepilation of eyelashes and eyelid plastic surgery, especially entropion. The most common indicated surgery in our clinic was amniotic membrane transplantation and retro position of muscular cutaneous leaf. 31 % of patients were diagnosed with MMP. Positive results of conjunctival biopsy were detected in48 % from 42 examined samples and 22 % from 32 examined samples had positive results of indirect immunofluorescence (anti-desmosoms). Conclusion: OCP diagnosis is established on the basis of patient´s ophthalmic history and clinical findings. Positive results of direct and indirect immunofluorescence support the diagnosis. Activity of the disease and progression of OCP is effectively suppressed by systemic immunosuppressive therapy (for example MM), mainly if started at early stage of the disease.

 ocular cicatricial pemphigoid immunosuppressive therapy direct and indirect immunofluorescence mycophenolate mofetil References Ahmee M, Zein G, Khawaja F. et al.: Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res 2004; 23: 579–92. Ahmend AR, Foster SC, Zaltas MM.: Association of DQw7 (HLA-DQβ1*0301) with ocular cicatricial pemphigoid, Proc Natl Acad Sci U S A 1991; 88: 11579–82. Bernard P, Vaillant L, Labeille B, et al.: Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Disease French Study group. Arch Dermatol 1995; 131; 48–52. Bertram F, Brocker EB, Zillikens D, et al.: Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Gemany. J Dtsch Dermatol Ges, 2009; 7: 434–40. Brunner M, Lacoste KJ, Bernauer W.: Control of ocular disease in mucous Canizares MJ, Smith DI, Conners MS at al.: Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol, 2006 Nov; 142(11): 1457–61. DaCosta J.: Ocular cicatricial pemphigoid masquerading as chronic conjunctivitis: a case report. Clin Ophthalmol, 2012; 6: 2093–5. Daniel E, Thorne JE, Newcomb CW et al.: Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol, 2010 Mar; 149(3): 423–32.e1–2. Doycheva D, Deuter C, Blumenstock G, at al.: Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid. Ocul Immunol Inflamm, 2011 Dec; 19(6): 431–8. Elder MJ, Bernauer W, Leonard J, Dart JK.: Progression of disease in ocular pemphigoid. Br J Ophthalmol, 1996; 80: 292–6. Elder MJ, Dart JK, Collin R.: Inferior retractor plication surgery for lower lid entropion with trichiasis in ocular cicatricial pemphigoid. Br J Ophthalmol, 1995 Nov; 79(11): 1003–6. Elder MJ, Lightman S, Dart JK., Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol, 1995 Mar; 79(3): 264–6. Foster CD.: Cicatricial pemphigoid. In: Cornea: Fundamentals, Diagnosis, and Management., ed 3 In“ Krachmer JH, Mannis MJ, Holland EJ, edsVol. 1. Philadelphia, Mosby Elsevier, 2011; p. 591–9. Foster CS, Chang PY, Ahmed AR: Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular ci- Gangaputra S, Newcomb CW, Liesegang TL et al.: Methotrexate for ocular inflammatory diseases. Ophthalmology, 2009 Nov;116(11): 2188–98.e1. Grau AE1, Setterfield J, Saw VP.: How to do conjunctival and buccal biopsies to investigate cicatrising conjunctivitis: improving the diagnosis of ocular mucous membrane pemphigoid. Br J Ophthalmol, 2013 Apr; 97(4): 530–1. Heffernan MP, Bentley DD.: Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol, 2006 Oct; 142(10): 1268–70. Hervás Ontiveros, Salom, España Gregori.: Methotrexate as a treatment in ocular cicatricial moderate pemphigoid. Arch Soc Esp Oftalmol, 2013 Dec 18. pii: S0365–6691(13): 00376–6. Hollick EJ1, Watson SL, Dart JK et al.: Legeais BioKpro III keratoprosthesis implantation: long term results in seven patients. Br J Ophthalmol,2006 Sep; 90(9): 1146–51. Chan LS, Ahmed AR, Anhalt GJ, et al.: The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment and prognostic indicators. Arch Dermatol, 2002; 138: 370–9. Chan LS.: Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid). Clin Dermatol, 2012 Jan-Feb; 30(1): 34–7. Chang JH, McCluskey PJ.: Ocular cicatricial pemphigoid: manifestations and management. Curr Allergy Asthma Rep, 2005 Jul;5(4): 333–8. Iakymenko S.: Forty-five years of keratoprosthesis study and application at the Filatov Institute: a retrospective analysis of 1 060 cases. Int J Ophthal - mol, 2013 Jun 18;6(3): 375–80. Kanski, J. J.: „Clinical Ophthalmology: A Systematic Approach“, Butteworth -Heinemann, 2007, s, 235-237, ISBN 9780702040931. 1979 through 2002 in the United States. Arch Dermatol, 2009 Sep; 145(9): 1005–8. Kharfi M, Khaled A, Anane R, et al.: Early onset childhood cicatricial pemphigoid: case report and review of the literature. Paediatr Dermatol, 2010; 27: 119–24. Kirzhner M1, Jakobiec FA.: Ocular cicatricial pemphigoid: a review of clinical features, immunopathology, differential diagnosis, and current management.Semin Ophthalmol, 2011 Jul-Sep; 26(4–5): 270–7. Letko E, Bhol K, Foster CS, Ahmed AR.: Influence of intravenous immunoglobulin therapy on serum levels of anti-β4 antibodies in ocular cicatricial pemphigoid. Curr Eye Res, 2000; 21: 646–54. Messmer EM1, Hintschich CR, Partscht K at al.: Ocular cicatricial pemphigoid. Retrospective analysis of risk factors and complications. Ophthalmologe, 2000 Feb; 97(2): 113–20. Miserocchi E1, Baltatzis S, Roque MR.: The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology. 2002 Jan;109(1):111-8 Mondino BJ, Brown SI.: Ocular cicatricial pemphigoid. Ophthalmology, 1981 Feb; 88(2): 95–100. Nottage JM1, Hammersmith KM, Murchison AP, et al.: Treatment of mucous membrane pemphigoid with mycophenolate mofetil. Cornea, 2013 Jun; 32(6): 810–5. Pasadhika S, Kempen JH, Newcomb CW et al.: Azathioprine for ocular inflammatory diseases. Am J Ophthalmol, 2009 Oct; 148(4): 500–509.e2. Pujari SS, Kempen JH, Newcomb CW et al.: Cyclophosphamide for ocular inflammatory diseases. Ophthalmology, 2010 Feb; 117(2): 356–65. Radford CF1, Rauz S, Williams GP et al.: Incidence, presenting features, and diagnosis of cicatrising conjunctivitis in theUnited Kingdom. Eye (Lond), 2012 Sep; 26(9):1199–208. Risser J1, Lewis K, Weinstock MA.: Mortality of bullous skin disorders from catricial pemphigoid: a preliminary report. Ophthalmology, 2010 May; 117(5): 861–9. Saw VP, Dart JK, Rauz S, et Wi al.: Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology, 2008; 115: 253–261. Saw VP, Dart JK.: Ocular mucous membrane pemphigoid: diagnosis and management strategies. Ocul Surf, 2008 Jul; 6(3): 128–42. Sobolewska B , Deuter C, Zierhut M.: Current medical treatment of ocular mucous membrane pemphigoid. Ocul Surf, 2013 Oct; 11(4): 259–66. Srikumaran D, Akpek EK.: Mucous membrane pemphigoid: recent advances. Curr Opin Ophthalmol, 2012 Nov; 23(6): 523–7. Thorne JE, Woreta FA, Jabs DA et al.: Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology, 2008 Dec; 115(12): 2146–2152. Thorne JE1, Anhalt GJ, Jabs DA.: Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology, 2004 Jan; 111(1): 45–52. Trimarchi M1, Bellini C, Fabiano B, et al.: Multiple mucosal involvement in cicatricial pemphigoid. Acta Otorhinolaryngol Ital, 2009 Aug; 29(4): 222–5. Tyagi S, Bhol K, Natarajan K at al.: Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci U S A,1996 Dec 10; 93(25): 14714–9. Williams GP, Radford C, Nightingale P, et al.: Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom. Eye, 2011; 25: 1207– Xu HH1, Werth VP, Parisi E, Sollecito TP.: Mucous membrane pemphigoid. Dent Clin North Am, 2013 Oct; 57(4): 611–30.